1OHASHI Y, NAKAI Y, TANAKA A, et al. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized dermatophagoides farinae extracts[J]. Acta Otolaryngol, 1998,118(6): 113-117.
4Pawankar R. Allergic rhinitis and asthma: the link, thenew ARIA classification and global approaches to treat, ment[J]. Curr Opin Allergy Clin Immunol(S0091-6749) ,2004,4(1) : 1-4.
7Amin H S, Liss G M, Bernstein D I. Evaluation of near- fatal reactions to allergen immunotherapy injections[J]. J Allergy Clin lmmunol,2006,117(1) :169 175.
9Nuhoglu Y, Ozumut S S, Ozdemir C, et al. Sublingual im munotherapy to house dust mite in pediatric patients with al- lergic rhinitis and asthma:a retrospective analysis o{ clinical course over a 3 year follow-up period[J]. J Investig Allergol Clin Immunol,2007,17(6) : 375- 378.
10Bukstein D, Luskin A T, Farrar J R. The reality of ad- herence to rhinitis treatment:identifying and overcoming the barriers[J]. Allergy Asthma Proc, 2011,32 (4) : 265- 271.